Gout, a painful joint condition, is on the rise globally, affecting even younger individuals. This surge is linked to ageing ...

For anyone unfamiliar with gout - and I envy you - it’s a condition that announces itself with all the subtlety of a fire ...

Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a ...

High uric acid, or hyperuricemia, quietly affects countless people-and often sparks painful gout attacks or kidney troubles ...

The burden of cardiovascular-kidney-metabolic (CKM) comorbidities among adults with gout is high, noted Chio Yokose, MD, MSc, ...

For $950 million upfront, Sobi will gain ownership to pozdeutinurad, an oral URAT1 inhibitor that performed well in Phase II ...

For centuries, alcohol and rich food were blamed for this painful condition. Now, a study of 2.6 million people proves that your DNA, not your dinner, is the real culprit.

Global study reveals alarming rise in gout cases among young people aged 15 to 39, with rates increasing 66% from 1990 to ...

The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist ...

Sobi has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics for $950m.